INHIBITEURS D'APOL1 ET LEURS PROCÉDÉS D'UTILISATION

The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).

Saved in:
Bibliographic Details
Main Authors CAO, Jingrong, WANG, Tiansheng, LEDFORD, Brian, SENTER, Timothy J, MEDEK, Ales, DENIS, Francois, FORTIER, Anne, NICOLAS, Olivier, DORSCH, Warren A, HU, Kan-Nian, COME, Jon H, SAYEGH, Camil, GAGNON, Kevin, WITKOS, Faith, KRUEGER, Elaine B, HAMEL, Martine, NANTHAKUMAR, Suganthini S, DAKIN, Leslie A, SHI, Yi, BRODNEY, Michael, SHRESTHA, Muna, ROSE, Peter
Format Patent
LanguageFrench
Published 27.10.2021
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).
Bibliography:Application Number: MA20190054538